Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
Go back to Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel| (NASDAQ: ACLX) | Delayed: 115.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.07 | 52 Week High | $ | |||
| Open | $115.07 | 52 Week Low | $ | |||
| Day High | $115.07 | P/E | N/A | |||
| Day Low | $115.07 | EPS | $ | |||
| Volume | 40,548 | |||||
| Gilead Sciences (NASDAQ: GILD) | Delayed: 131.27 +5.30 (4.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.97 | 52 Week High | $108.63 | |||
| Open | $126.72 | 52 Week Low | $71.39 | |||
| Day High | $131.58 | P/E | 72.52 | |||
| Day Low | $126.46 | EPS | $1.81 | |||
| Volume | 8,091,211 | |||||
